4/A: Artivion Director Corrects Equity Grant Filing

Director Marna P. Borgstrom filed an amendment to correct administrative errors regarding a restricted stock award grant date and share count.

Summary

• Director Marna P. Borgstrom filed an amendment to a previously submitted Form 4.
• The amendment corrects the grant date of a restricted stock award from May 14, 2026, to May 18, 2026.
• The number of shares granted was corrected to 7,576 from the previously reported 7,850.
• The total beneficial ownership was updated to 56,664 shares from 56,938.
• The vesting date for the award is confirmed as May 18, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative update with no impact on the company's financial outlook or strategic direction.

Positives

• Transparency in correcting administrative reporting errors promptly.

Negatives

• Initial filing contained inaccurate data regarding share counts and dates.

Risks

• None identified; this is a routine administrative correction.

Future Outlook

The restricted stock award is scheduled to vest on May 18, 2027, subject to the terms of the company's Equity and Cash Incentive Plan.

Industry Context

StockSavvy.ai notes that administrative amendments to Form 4 filings are common in the medical device industry and generally do not reflect underlying operational or financial performance shifts.

Comparison to Industry Standards

• The filing follows standard SEC disclosure requirements for director equity compensation.
• The correction process aligns with typical corporate governance practices for rectifying clerical errors in executive reporting.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine correction of director equity reporting.

Next Steps

• Vesting of the restricted stock award on May 18, 2027.

Key Dates

Keywords

Artivion, AORT, Form 4, Insider Trading, Director Compensation, Equity Grant